When compared to the pCR group, the non-pCR group displayed a higher clinical stage, larger tumor size, greater number of patients with lymph node involvement and HER2 expression with an Immunohistochemistry (IHC) score of 2+, which was further confirmed via fluorescence in situ hybridization (FISH+). This evidence concerns the gene ERBB2 and neoplasm.